379 related articles for article (PubMed ID: 22419280)
1. Acellular vaccines for preventing whooping cough in children.
Zhang L; Prietsch SO; Axelsson I; Halperin SA
Cochrane Database Syst Rev; 2012 Mar; (3):CD001478. PubMed ID: 22419280
[TBL] [Abstract][Full Text] [Related]
2. Acellular vaccines for preventing whooping cough in children.
Zhang L; Prietsch SO; Axelsson I; Halperin SA
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD001478. PubMed ID: 25228233
[TBL] [Abstract][Full Text] [Related]
3. Acellular vaccines for preventing whooping cough in children.
Zhang L; Prietsch SO; Axelsson I; Halperin SA
Cochrane Database Syst Rev; 2011 Jan; (1):CD001478. PubMed ID: 21249646
[TBL] [Abstract][Full Text] [Related]
4. WITHDRAWN: Acellular vaccines for preventing whooping cough in children.
Tinnion O; Hanlon M
Cochrane Database Syst Rev; 2008 Apr; (2):CD001478. PubMed ID: 18425874
[TBL] [Abstract][Full Text] [Related]
5. WITHDRAWN: Acellular vaccines for preventing whooping cough in children.
Tinnion ON; Hanlon M
Cochrane Database Syst Rev; 2007 Jul; (3):CD001478. PubMed ID: 17636677
[TBL] [Abstract][Full Text] [Related]
6. Acellular vaccines for preventing whooping cough in children.
Tinnion ON; Hanlon M
Cochrane Database Syst Rev; 2000; (2):CD001478. PubMed ID: 10796648
[TBL] [Abstract][Full Text] [Related]
7. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
8. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
Bar-On ES; Goldberg E; Hellmann S; Leibovici L
Cochrane Database Syst Rev; 2012 Apr; (4):CD005530. PubMed ID: 22513932
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
[TBL] [Abstract][Full Text] [Related]
10. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.
Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; uberall M; Laussucq S; Eckhardt T; Meyer M; Engelhardt R; Christenson P
Pediatrics; 1998 Jan; 101(1 Pt 1):1-11. PubMed ID: 9417143
[TBL] [Abstract][Full Text] [Related]
11. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.
Olin P; Rasmussen F; Gustafsson L; Hallander HO; Heijbel H
Lancet; 1997 Nov; 350(9091):1569-77. PubMed ID: 9393335
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
13. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
Matheson AJ; Goa KL
Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
[TBL] [Abstract][Full Text] [Related]
14. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
Bar-On ES; Goldberg E; Fraser A; Vidal L; Hellmann S; Leibovici L
Cochrane Database Syst Rev; 2009 Jul; (3):CD005530. PubMed ID: 19588375
[TBL] [Abstract][Full Text] [Related]
15. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic treatment of the cough in whooping cough.
Wang K; Bettiol S; Thompson MJ; Roberts NW; Perera R; Heneghan CJ; Harnden A
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD003257. PubMed ID: 25243777
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of acellular pertussis vaccines: the Mainz study and other recent studies.
Weigl JA; Bock HL; Clemens R; Zepp F; Habermehl P; Beutel K; Müschenborn S; Sümenicht G; Schuind A; von König CH; Neiss A; Laukamp S; Kiederle S; Schmitt HJ
Ann Acad Med Singap; 1997 May; 26(3):320-5. PubMed ID: 9285026
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.
Heininger U; Cherry JD; Stehr K; Schmitt-Grohé S; Uberall M; Laussucq S; Eckhardt T; Meyer M; Gornbein J
Pediatrics; 1998 Sep; 102(3 Pt 1):546-53. PubMed ID: 9738175
[TBL] [Abstract][Full Text] [Related]
19. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
20. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
